innerpage-banner.jpg

News Room / GVK Biosciences licenses its Toxicity Database to AstraZeneca

  • Font SizeAA

GVK Biosciences licenses its Toxicity Database to AstraZeneca

Hyderabad- India, February 18th 2008

GVK Biosciences (GVK BIO) announced that it has licensed its Mechanism Based Toxicity Database (MBT) to AstraZeneca. MBT has over 13,000 drug and drug like compounds, their routes of metabolism, toxic indications and the numerical values of the measures of toxicity. The data has been manually curated from over 35,000 individual references. The license represents an extension of the existing license of all the GVK BIO Target and Drug databases. The GVK BIO Databases contain over 3.2 million compounds manually curated from patents and journals and represent over 7 million quantitative SAR data points.

Sreeni Devidas, Vice President Business Development, GVK BIO said: “We are excited to extend our
relationship with AstraZeneca. The MBT provides easily accessible information on known toxic effects of
over 13,000 compounds from the literature, which will be made available to researchers in AstraZeneca”.

Informatics at GVK BIO

The Informatics division is responsible for analyzing data to transform chemical / biological patterns into
knowledge. Informatics offers Custom Curation, Cheminformatics and Bioinformatics services to global
clients. It also licenses and sells databases to Biotech and Pharma companies. GVK BIO’s clients include 15 of the top 20 Pharmaceutical companies.

About GVK BIO

GVK Biosciences (www.gvkbio.com), India’s premier Contract Research Organization, delivers integrated
research services to global pharmaceutical and biotech companies. The company accelerates the Drug
Discovery and Development process of its customers through science and innovation. Currently the
company has more than 1,300 employees spread across facilities in Hyderabad, Gurgaon.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development,
manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $29.559 billion and leading
positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection
products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4 Good Index.

For any further information, please contact:

Sreeni Devidas
Vice President – Business Development
GVK Biosciences Private Limited
Columbia, MD 21045
T 001-443-838-6260
E sreeni.devidas@gvkbio.com
W www.gvkbio.com

Sharada Alvakonda
Dy.General Manager– Corporate Communications
GVK Biosciences Private Limited
Hyderabad